Replies to post #97433 on Biotech Values

[DewDiligence]

There’s a big gap between $300M and $4B! I’ll bet Tasigna’s sales will more than double from 2Q10 to 2Q11.

[DewDiligence]

FDA approves BMY’s Sprycel in first-line CML:

http://finance.yahoo.com/news/FDA-Approves-SPRYCEL-bw-1295734077.html?x=0&.v=1

NVS’ Tasigna received FDA approval in this indication in Jun 2010 (#msg-51437844). Let the battle for the first line begin!